How to Buy Procept Biorobotics Stock
Procept Biorobotics Corp
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology.
Procept Biorobotics stock last closed at $53.98, down 4.14% from the previous day, and has increased 1.89% in one year. It has overperformed other stocks in the Medical Devices industry by 0.15 percentage points. Procept Biorobotics stock is currently +14.75% from its 52-week low of $47.04, and -48% from its 52-week high of $103.81.
There are currently 54.82M shares of PRCT outstanding. The market capitalization of PRCT is $2.96B. In the last 24 hours, 941,185 PRCT shares were traded.
How to Buy Procept Biorobotics Stock
Wondering how to invest in Procept Biorobotics stock? Here's how.
- Figure out where to buy Procept Biorobotics stock: You need to pick an online brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you figure out where to buy Procept Biorobotics stock.
- Sign up for a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Put funds into your brokerage account: Pick your payment method and add your details.
- Evaluate Procept Biorobotics stock: The Procept Biorobotics ticker symbol is PRCT. Is Procept Biorobotics stock a good investment? Should you buy shares of PRCT? How do PRCT's underlying business fundamentals look? Do top analysts think Procept Biorobotics is a good buy? Why has PRCT's stock price moved recently? (Hint: Our stock market research tools can help you figure out if PRCT is a good stock to buy).
- Place your PRCT trade: Decide if you will purchase PRCT shares at the current market price or use a limit order to buy PRCT shares at a particular price.
- Get key alerts regarding your PRCT investment: Create a watchlist to get the latest news on your investment in Procept Biorobotics stock.
Step 1: Figure out where to buy Procept Biorobotics stock
You will need an online brokerage account in order to access the NASDAQ market and buy PRCT stock.
Our preferred brokerage: eToro
Based on our experience, eToro is the best brokerage. eToro gives you:
- You can invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to world financial markets: From Tech to Healthcare, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro offers a community with more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Sign up for a brokerage account
Now that you've selected the best brokerage, you need to fill out some personal details so you can buy PRCT today.
How to Set Up a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to open a new trading account.
- Submit your data by hitting the "Create Account" button. Get started with eToro today
Step 3: Put funds into your brokerage account
Now that you've created your account on the best stock trading app, you can securely and quickly fund your account:
Watch this video walkthrough if you need help transferring money into your new brokerage account.
Step 4: Evaluate Procept Biorobotics stock
After you have identified the best place to buy Procept Biorobotics stock, it's very important to analyze their stock before you buy, so you truly comprehend the risk as well as the upside.
Overview of key PRCT info
Fundamentals of Procept Biorobotics
WallStreetZen was built to help average investors perform more accurate fundamental analysis quickly.
You can see all of the due diligence checks on PRCT's stock page.
Is PRCT stock undervalued or overvalued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge PRCT's intrinsic value.
Using relative valuations measures:
- PRCT could be overvalued based on its P/B ratio of 7.36x, relative to Medical Devices industry P/B ratio of 3.94x
You can access additional valuation research on PRCT's stock here.
PRCT Financials at a glance
Passed Financial Due Diligence Checks:
- There are more short-term assets than long-term liabilities on the PRCT balance sheet.
- There are more short-term assets than short-term liabilities on the PRCT balance sheet.
- PRCT has cash burn of 103622000. It has enough cash and short-term investments to cover this for at least one year.
- PRCT has a low debt to equity ratio of 0.33.
- Total PRCT debt is lower than 5 years ago, relative to shareholder equity.
- PRCT has $333.73M in cash and short term investments. This is enough to cover its annual cash burn of $103.62M.
Failed Financial Due Diligence Checks:
- PRCT profit margin has gone up by 0.37 percentage points in the past year, but the company is still unprofitable.
Is PRCT stock a Buy, Hold, or Sell, according to analysts?
Out of 5 Equities analysts who track PRCT, the consensus analyst rating on Procept Biorobotics is a Strong Buy
It's important to keep in mind that analyst ratings are not recommendations, nor are they investment advice.
You can dig deeper into what analysts are forecasting on the Procept Biorobotics stock forecast page.
Metrics for Advanced PRCT Traders
PRCT Earnings
Last year, PRCT revenue was $224.50M. During the last 5 year, PRCT's revenue has gone up by 105.21% per year. This was faster than the Medical Devices industry average of 9.9%.
Learn more about PRCT's earnings and revenue performance here.
What are PRCT executives and large shareholders up to?
Over the last year, executives and large shareholders at PRCT have sold more shares than they have bought.
Alaleh Nouri, EVP CLO CORP. SEC. of PRCT, was the latest PRCT insider to sell. They sold $18,030.96 worth of PRCT shares on Mar 18, 2025.
Research more about who owns PRCT stock here.
Does PRCT stock generate passive income?
No, Procept Biorobotics doesn't provide an income stream by paying out dividends.
Get analysis from other traders
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Place your PRCT trade
You have two primary options:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are generally the best for newer investors. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at an exact price limit, use a limit order.
Click the Open button and your broker will place your order.
If you want more help buying stocks on eToro, click the helpful video below:
Step 6: Get key alerts regarding your PRCT investment
Now that you own some PRCT stock, you'll want to stay up-to-date on your shares.
Put PRCT on a watchlist to track the most important metrics related to your PRCT stock.
PRCT Feed
How to Buy Stock in Procept Biorobotics
To reiterate, here are the 6 steps you need to take to buy Procept Biorobotics stock right now:
- Figure out where to buy Procept Biorobotics stock
- Sign up for a brokerage account
- Put funds into your brokerage account
- Evaluate Procept Biorobotics stock
- Place your PRCT trade
- Get key alerts regarding your PRCT investment
If you require a online brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you want to keep tabs on your new investment in Procept Biorobotics, get started below.
Other "How To" Guides You May Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.